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Introduction: Colorectal cancer is a disease inﬂuenced by genetic and environmental factors.
Medicinal fungi and/or its extracts have been used in the adjuvant therapy of cancer because
of  their pharmacological, nutritional and immunomodulatory properties.
Objective: To evaluate the anthropometric proﬁle of colorectal cancer women after dietary
supplementation with Agaricus sylvaticus fungus.
Methods: Randomized, double-blind, placebo-controlled clinical trial was conducted in a
public hospital in the Federal District – Brazil for six months. Sample of 32 patients with
colorectal cancer, female, was separated into two groups: supplemented with Agaricus syl-
vaticus  (30 mg/kg/day) and placebo. We  conducted anthropometry (weight, height, body mass
index, arm circumference, triceps skinfold, arm muscle circumference and fat percentage)
during the treatment. The results were analyzed at three different times (before the start of
treatment, three months and after six months supplementation) using the Microsoft Excel
2007  and SPSS 19.0, using Student’s t-test and F, with signiﬁcance for p ≤ 0.05.
Results: The Agaricus sylvaticus group showed a signiﬁcant increase in body mass index, arm
circumference, percent body fat and triceps skinfold, and non-signiﬁcant increase in arm
muscle  circumference after six months of supplementation. These results were not observed
in  the placebo group.
Conclusion: The results suggest that dietary supplementation with Agaricus sylvaticus is capa-
ble  to have beneﬁts in anthropometric parameters of women with colorectal cancer.de Brasileira de Coloproctologia. Published by Elsevier Editora Ltda. All©  2015 Sociedarights reserved.
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Ensaio  clínico  duplo  cego,  randomizado  e  placebo  controlado  com  fungos
Agaricus  sylvaticus  no  perﬁl  antropométrico  de  mulheres  com  câncer
colorretal
Palavras-chave:
Antropometria
Câncer colorretal
Fungos Agaricus sylvaticus
r  e  s  u  m  o
Introduc¸ão: O câncer colorretal é uma doenc¸a inﬂuenciada por fatores genéticos e ambi-
entais. A utilizac¸ão de fungos medicinais e/ou de seus extratos tem sido utilizada no
adjuvante tratamento do câncer devido às suas propriedades farmacológicas, nutricionais
e  imunomoduladoras.
Objetivo: Avaliar o perﬁl antropométrico de mulheres com câncer colorretal após
suplementac¸ão  dietética com fungos Agaricus sylvaticus.
Métodos: Ensaio clínico randomizado, duplo-cego, placebo-controlado realizado em um hos-
pital público do Distrito Federal Brasil por seis meses. Amostra constituída por 32 pacientes
com  câncer colorretal, sexo feminino, separados em dois grupos: suplementado com Agar-
icus  sylvaticus (30 mg/kg/dia) e placebo. Realizou-se a antropometria (peso, estatura, índice
de  massa corporal, circunferência do brac¸o, dobra cutânea tricipital, circunferência muscu-
lar do brac¸o e percentual de gordura) ao longo do tratamento. Os resultados foram analisados
em  três momentos distintos (antes do início do tratamento, com três meses e após seis
meses de suplementac¸ão), utilizando os programas Microsoft Excel 2007 e SPSS 19.0, por
meio dos testes T-student e F, com signiﬁcância para p ≤ 0,05.
Resultados: O grupo Agaricus sylvaticus apresentou aumento signiﬁcativo de índice de massa
corporal, circunferência do brac¸o, percentual de gordura corporal e dobra cutânea tricip-
tal  e, aumento não signiﬁcativo de circunferência muscular do brac¸o após seis meses de
suplementac¸ão.  Esses resultados não foram observados no grupo placebo.
Conclusão: Os resultados sugerem que a suplementac¸ão dietética com Agaricus sylvaticus
é  capaz de exercer benefícios nos parâmetros antropométricos de mulheres com câncer
colorretal.
©  2015 Sociedade Brasileira de Coloproctologia. Publicado por Elsevier Editora Ltda.
Todos os direitos reservados.
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owadays, due to its increasing incidence, cancer has become
 public health problem worldwide,1 pari passu with the pro-
ressive aging of the population, as a consequence of an
ncreased life expectancy.2
Colorectal cancer is a common and deadly disease, inﬂu-
nced by genetic and environmental factors and also by the
utual inﬂuence of both. Genetic predisposition is a predom-
nant risk factor for some individuals; however, environmental
actors, including diet, physical activity, smoking and obesity,
re also included among high-risk factors.2
As for the risk of developing colorectal cancer, patients can
e divided as follows: those less than 50 years and no fam-
ly history of colorectal cancer are at low risk; those aged 50 or
ore and with no other risk factors are included in the average
isk group; patients with personal history of polyps or colorec-
al cancer, or with a family history of colorectal cancer or with
rst-degree relatives diagnosed with polyps are classiﬁed as
igh-risk people; and ﬁnally, the very high-risk classiﬁcation
omprises those patients with polypoid syndromes, or who
re suffering from inﬂammatory bowel disease.3
Most often, a diagnosis of cancer leads to a phase of
uch anxiety and distress, possibly triggering a picture of
epression. In turn, the depression comes in association with
omatic symptoms such as loss of appetite and fatigue, whichmay also be associated with the catabolism and/or treatment
of the disease.4
The use of medicinal fungi and/or their extracts as
dietary supplements has increased considerably, thanks to
its anti-tumor, anticarcinogenic, antiviral, anti-inﬂammatory,
hypoglycemic, hypocholesterolemic and hypotensive effects,
among others, and these products may be recommended as
adjuvants in the treatment of malignant neoplasms.5
Considering the prominence of this theme, this study
aimed to evaluate the anthropometric proﬁle of women with
colorectal cancer after dietary supplementation with the fun-
gus Agaricus sylvaticus.
Methods
Study  design
The study consists of a randomized, double-blind, placebo-
controlled study, which was approved by the Ethics Committee
on Human Research, State Secretariat of Health, Distrito Fed-
eral (CEP/SES/DF) under Protocol 051/04. The patients’ free and
informed consent (FIC) was obtained, and their participation
was voluntary. The study was conducted at the Proctology
Outpatient Clinic, Hospital de Base do Distrito Federal, Brazil,
between November 2004 and July 2006.
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The randomization procedure occurred through sequential
numbers randomly generated by computer, where each ran-
dom number corresponded to a group receiving the fungus
(Group A) or placebo (Group B). These numbers were inserted
into opaque, not translucent and closed envelopes, with the
generation of the number sequence performed by a researcher
blinded to the study, after selection of patients with inclusion
and exclusion criteria. The envelopes were opened sequen-
tially as the patients were consecutively recruited for the study
and contained the group to which the patient would belong.
Only after performing the statistical analysis, it was revealed
which group had received placebo and which received Agaricus
sylvaticus.
Patients
The sample consisted of patients with colorectal cancer
divided into two groups: those who received placebo and
those supplemented with Agaricus sylvaticus.  The following
inclusion criteria should be fulﬁlled: female patients with a
conﬁrmed diagnosis of colorectal cancer in the postopera-
tive phase, from three months to two years of surgery, and
older than 20 years. Exclusion criteria were: pregnant women,
breastfeeding mothers, bedridden individuals, physically dis-
abled people, patients using an alternative therapy or with
other chronic non-communicable diseases, and in metastasis
process.
Agaricus  sylvaticus  extract
With a widespread geographical distribution and naturally
occurring in Brazil, Agaricus sylvaticus was ﬁrst described in
Switzerland. Its identiﬁcation was conﬁrmed by the London
Royal Botanic Gardens, whose documentation was provided
by the Instituto de Botânica, Environment State Secretariat,
São Paulo, in November 10, 1995. The Agaricus sylvaticus fungus
(Family: Agaricaceae), whose popular name is Sun Mushroom,
was obtained from a producer duly accredited by the Empresa
Brasileira de Pesquisa Agropecuária – Embrapa, from Tapiraí,
State of Sao Paulo, Brazil. The fungus extract was obtained by
soaking the dehydrated material in hot water during 30 min;
then, the material was liquiﬁed, sieved and dried in a des-
iccator. The analysis of Agaricus sylvaticus composition was
performed by the Japan Food Research Laboratories Center and
revealed the presence of carbohydrates (18.51 g/100 g), lipids
(0.04 g/100 g), ergosterol (624 mg/100 g), proteins (4.99 g/100 g),
amino acids (arginine – 1.14%; lysine – 1.23%, histidine –
0.51%, phenylalanine – 0.92%, tyrosine – 0.67%, leucine – 1 43%
methionine – 0.32%, valine – 1.03%, alanine – 1.28% glycine –
0.94%, proline – 0.95%, glutamic acid – 3.93%, serine – 0 96%,
threonine – 0.96%, aspartic acid – 1.81%, tryptophan – 0.32%
cysteine – 0.25%) and trace amounts of micronutrients.
The dry extract was transformed into tablets, in accordance
with pharmacotechnical procedure. The dosage of the fungus
administered to patients from the supplemented group was
equivalent to 30 mg/kg/day, divided into two daily doses (six
tablets a day, three in the morning and three in the afternoon,
in between meals), considering the mean weight of the study
population over a period of six months. As for the group of
patients who received placebo, the tablets were administered0 1 5;3  5(1):28–34
in the same quantities, with the same excipients and energy,
but without the extract of Agaricus sylvaticus (in its place, the
placebo group received starch).
Clinical  evolution
Patients were followed for six months. During the ﬁrst three
months, the visits were held fortnightly for clinical assess-
ment and, in the last three months, the visits were held every
30 days.
The food anamnesis (semiquantitative and 24-h recall food
consumption frequency questionnaire) was held on the ﬁrst
and last days of consultation. However, the patients were
instructed to remain with the usual diet, in order not to inter-
fere with the intervention, although during treatment they
have received guidelines on how to maintain a healthy diet.
After a 6-month follow-up, an individualized diet was sug-
gested for all patients, who, when necessary, were referred
to other health professionals.
The anthropometric assessment was performed using
body mass index (BMI), triceps skinfold thickness (TSF), arm
circumference (AC), arm muscle circumference (AMC) and
body fat percent (%BF). However, for statistical purposes, we
extracted the average of the results obtained in three different
times: before starting supplementation, after three months of
treatment and after six months of treatment.
All patients were followed weekly by researchers to clarify
any doubts, check on the proper use of the mushroom and for
conﬁrmation of the schedule, ensuring greater adherence to
treatment and control on the continuity of the study.
We considered as dropouts those patients who did not
attend the consultations during the full period of six months.
Those patients who died before the end of treatment were
excluded from the sample.
Anthropometric  assessment
A special form of anthropometric assessment, to be ﬁlled in all
the consultations, was used. Weight determination was per-
formed with the patient barefooted, wearing light clothing and
without jewellery interfering with the measurement results.
The patient should remain standing in the center of the scale,
with her body weight equally distributed between both feet.6
In order to obtain this variable, a Plenna® – Resolve digital
scale (MEA-02500 model) with bioimpedance (BIA), capacity of
150 kg, with 0.1 kg variation and properly calibrated was used.
For height measurement, the barefooted patient should
stay upright and in an erect position, with her body lifted at
maximum extension, head up, looking forward, in a Frankfurt
position, with her back and the back of her knees touching the
wall and with feet together.6 The Frankfurt anatomical plane
extends from the bottom margin of the eye socket to the top
border of the auditory canal.7 Patients’ height was measured
only once, in centimeters (cm), with a 150-cm long inelastic
measuring tape attached to a ﬂat wall without baseboard and
ﬁxed at 50 cm from the ground. A wood square was placed on
top of the head of the patient; with this, we obtained a measure
with 0.1-cm accuracy.
After data acquisition (weight and height), BMI  was
obtained by dividing the patient’s weight in kilograms by her
). 2 0 1 5;3  5(1):28–34 31
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Fig. 1 – Evolution of body mass index (BMI) of women with
colorectal cancer in placebo (n = 16) and Agaricus sylvaticus
(n = 16) groups, treated at the Proctology Outpatient Clinic,
Hospital de Base do Distrito Federal, throughout the clinical
follow-up. Placebo: p = 0.01 and p = 0.06 and Agaricus
sylvaticus:  p = 0.02 and p = 0.02, after three and six months,
months of supplementation (Fig. 2).
As for tricipital skinfold thickness, it was observed that
the placebo group had an initial mean of 19.53 ± 8.27 mm for
26.5
27
27.5
28
28.5
29
29.5
30
Start 3 months 6 months
Ar
m
 c
irc
um
fe
re
nc
e 
(cm
)
Follow-up
Agaricus sylvaticus Placebo
Fig. 2 – Arm circumference (AC) of women with colorectal
cancer of placebo (n = 16) and Agaricus sylvaticus (n = 16)
groups treated at the Proctology Outpatient Clinic, Hospitalj coloproctol (rio j
eight in meters squared. BMI  values <18.5 kg/m2 would char-
cterize thinness; ≥18, 5 kg/m2 and <25 kg/m2, normal weight;
25 kg/m2 and <30 kg/m2, overweight; and ≥30 kg/m2, obesity,
ccording to the classiﬁcation recommended by World Health
rganization.8
TSF was measured using a Cescorf® quick-reading com-
ass, with a range up to 60 mm and accuracy of ±1 mm.  Three
onsecutive measurements were obtained from TSF, and the
rithmetic average of the measured values was considered.
s for AC measurement, an inextensible-material, 150-cm
ength, 1-cm scale measuring tape was used. The AMC value
as obtained by the formula: AMC  = AC – (0.314 × TSF).8
TSF, AC and AMC  measures were compared to a
risancho’s9 reference standard, and the adequacy was cal-
ulated by dividing the values obtained by the 50th percentile
nd multiplying the result by 100. As to the nutritional status
lassiﬁcation, the following values were considered: obesity:
120%, overweight: 110–120%, normal weight: 90–110%, mild
alnutrition: 80–90%, moderate malnutrition: 70–80% and
evere malnutrition: <70%.10
The body fat percentage (%BF) was obtained also using the
lenna® digital scale.
tatistical  analysis
he presented values were compared and analyzed applying
-Student and F statistical tests, using Microsoft Excel 2007
nd SPSS (Statistical Package for the Social Sciences, SPSS Inc,
hicago, USA) for Windows, version 19.0. The accepted statis-
ical signiﬁcance probability was p < 0.05.
esults
fter a follow-up of six months in the Proctology Outpatient
linic, Hospital de Base do Distrito Federal, a total of 40 women
ith colorectal cancer who  met  the inclusion and exclusion
riteria agreed to participate in the research, and, of these
atients, two died and six dropped out for various reasons.
he ﬁnal sample consisted of 32 patients with a mean age of
6.66 ± 14.07 years, at stages I (n = 4), II (n = 12) and III (n = 16),
eparated into groups receiving placebo (n = 16) and Agaricus
ylvaticus (n = 16). The mean ages were 57.67 ± 13.42 years and
5.87 ± 15.11 years for placebo and Agaricus sylvaticus sup-
lemented groups, respectively, with no difference between
roups (p = 0.39).
As for the body mass index, we observed that the
lacebo group had an initial BMI  of 24.25 ± 5.33 kg/m2; after
hree months, a signiﬁcant increase in BMI was noted
from 24.25 ± 5.33 kg/m2 to 24.40 ± 5.15 kg/m2, p = 0.01) and
n the sixth month, there was a further increase (from
4.25 ± 5.33 kg/m2 to 24.71 ± 4.73 kg/m2, p = 0.06), but this last
esult was not statistically signiﬁcant (Fig. 1).
The supplemented group showed an initial BMI of
4.44 ± 4.59 kg/m2; after three months, a signiﬁcant increase
o 24.91 ± 4.18 kg/m2 (p = 0.02) was observed, and after six
2onths a further signiﬁcant increase to 25.16 ± 3.92 kg/m
ccurred, compared to baseline (p = 0.02) (Fig. 1).
Regarding arm circumference (AC), in the placebo group an
nitial value of 28.68 ± 5.80 cm for this variable was observed;respectively. Student’s t-test.
after three months, this value had suffered a signiﬁcant
decline, to 27.88 ± 4.56 cm (p = 0.05) and, after six months,
a non-signiﬁcant increase, to 28.39 ± 4.39 cm (p = 0.31), was
observed (Fig. 2).
The Agaricus sylvaticus group presented initial values of
28.66 ± 4.19 cm for AC, with a signiﬁcant increase over three
(29.47 ± 4.10 cm,  p = 0.01) and six (29.68 ± 3, 74 cm;  p = 0.0001)de Base do Distrito Federal, throughout the clinical
follow-up. Placebo: p = 0.05 and p = 0.31 and Agaricus
sylvaticus:  p = 0.01 and p = 0.0001, after three and six
months, respectively. Student’s t-test.
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Fig. 3 – Tricipital skin fold (TSF) of women with colorectal
cancer of placebo (n = 16) and Agaricus sylvaticus (n = 16)
groups treated at the Proctology Outpatient Clinic, Hospital
de Base do Distrito Federal, throughout the clinical
follow-up. Placebo: p = 0.14 and p = 0.19 and Agaricus
sylvaticus:  p = 0.16 and p = 0.05, after three and six months,
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Fig. 4 – Arm muscle circumference (AMC) of women with
colorectal cancer of placebo (n = 16) and Agaricus sylvaticus
(n = 16) groups treated at the Proctology Outpatient Clinic,
Hospital de Base do Distrito Federal, throughout the clinical
follow-up. Placebo: p = 0.14 and p = 0.03 and Agaricus
sylvaticus: p = 0.10 and p = 0.22, after three and six months,
than 50 years, and 75% of cases affect individuals without
other risk factors, besides age.
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Fig. 5 – Body fat percentage (%BF) of women with colorectal
cancer of placebo (n = 16) and Agaricus sylvaticus (n = 16)
groups treated at the Proctology Outpatient Clinic, Hospital
de Base do Distrito Federal, throughout the clinicalrespectively. Student’s t-test.
TSF. After an interval of three months, there was an increase
to 20.43 ± 9.14 mm (p = 0.14) and after six months, a further
increase to 20.42 ± 8.33 mm (p = 0.19). But these changes were
not statistically signiﬁcant (Fig. 3).
Within three months of supplementation, the Agaricus syl-
vaticus group showed a non-signiﬁcant increase in TSF (from
21.41 ± 7.44 mm to 22.38 ± 5.95 mm;  p = 0.16), followed after
six months by a signiﬁcant increase (from 21.41 ± 7.44 mm to
23.66 ± 5.62 mm,  p = 0.05) (Fig. 3).
In the placebo group, after arm muscle circumference
measurement, a non-signiﬁcant decrease after three months
(from 23.44 ± 4.42 cm to 22.82 ± 3.16 cm,  p = 0.14) and a sig-
niﬁcant decrease after six months (from 23.44 ± 4.42 cm to
22.30 ± 3.29 cm,  p = 0.03) were observed (Fig. 4).
These ﬁndings were not found in the Agaricus syl-
vaticus group, which increased its AMC  after three (from
21.94 ± 2.61 m to 22.45 ± 2.44 cm,  p = 0.10) and six (from 21,
94 ± 2.61 cm to 22.28 ± 2.65 cm,  p = 0.22) months of supplemen-
tation, although these changes were not signiﬁcant (Fig. 4).
As to the percentage of body fat, the placebo group pre-
sented initially a %BF of 36.33 ± 8.44%. After three months, this
variable had increased (from 36.33 ± 8.44% to 36.46 ± 7.25%,
p = 0.44) and in the sixth month, a new increase was again
noted (from 36.33 ± 8.44% to 37.60 ± 8.07%, p = 0.19). But these
changes were not statistically signiﬁcant (Fig. 5).
The Agaricus sylvaticus group presented an initial %BF of
36.88 ± 7.33%. After three months, a non-signiﬁcant increase
to 37.88 ± 6.60% (p = 0.09) was found, and after six months a
signiﬁcant increase to 39.56 ± 8.68% (p = 0.04) was observed
(Fig. 5).Discussion
In this study, the sample was conveniently composed of 100%
of women with colorectal cancer. Scientiﬁc evidence suggestsrespectively. Student’s t-test.
that colorectal cancer is more  prevalent in women, affecting
more and more  often the left colon.11 In Brazil, the Instituto
Nacional do Câncer (INCA) registry for 2012 estimated the
occurrence of 14,180 new cases of colorectal cancer in men
and of 15,960 cases in women, corresponding to an estimated
risk of 15 new cases per 100,000 men  and 16 new cases out of
every 100,000 women.12
The mean age of our patients was 55 and 57 years for
placebo and Agaricus sylvaticus groups, respectively. In these
groups, the minimum and maximum ages were 32 and 77
years, respectively. According to Cozerattolini et al.,13 more
than 90% of colon and rectal cancers relate to individuals olderfollow-up. Placebo: p = 0.44 and p = 0.19 and Agaricus
sylvaticus: p = 0.09 and p = 0.04, after three and six months,
respectively. Student’s t-test.
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In this study, both placebo and Agaricus sylvaticus groups
ad an initial BMI  within the normal weight range, with a
endency to be overweight. Scientiﬁc studies have shown a
ositive correlation between overweight, obesity and risk of
eveloping several types of cancer, as well as in mortality from
his disease. It is expected that the probable mechanism is
nterconnected with hyperinsulinemia and with a high level
f insulin-dependent growth factor (IGF-1) and of those pro-
eins that bind to IGF-1, as well as with the practice of diets
haracterized by too much energy consumption.13
There is a higher correlation between excess weight and
isk of colorectal cancer, in which the abdominal or central
istribution of body fat is the main component of increasing
his risk, as this occurrence is robustly linked to insulin resis-
ance and hyperinsulinemia.13 However, in this study, visceral
at was not evaluated.
Clinical and experimental studies show that the diet sup-
lemented with Agaricus sylvaticus and other fungi promotes
ositive effects with respect to nutritional, medicinal and
harmacological effects, and that these supplements can be
sed as adjuvants in cancer treatment.14 Medicinal fungi exert
nabolic effects, because they contain all the essential amino
cids, plus immunonutrients like arginine and glutamine that,
n times of metabolic stress, become conditionally essential,
ontributing to improvements in nitrogen balance.1,15
In this study, the Agaricus sylvaticus group obtained bet-
er anthropometric results (BMI, AC, TSF, %BF) versus placebo,
ncluding in relation to lean body mass, despite no signiﬁ-
ant ﬁnding. Scientiﬁc evidence suggests that medicinal fungi
ave bioactive compounds able to prevent the muscle protein
atabolism commonly present in these patients, explaining in
art the results observed.15–17
The mechanisms of action of existing bioactive compounds
n fungi are not yet fully explained in the literature, but
cientiﬁc studies suggest that these substances can modu-
ate carcinogenesis, not only in the early stages, but also in
dvanced phases in the progression of the disease, especially
y stimulating the immune system.14
We  found no scientiﬁc papers in the literature that eval-
ated anthropometry and/or the nutritional status of cancer
atients after dietary supplementation with medicinal fungi,
ncluding those of the Agaricaceae family, species Agari-
us sylvaticus.  However, clinical studies show that medicinal
ungi are able to modulate the metabolism of carbohydrates,
roteins and lipids, besides exerting beneﬁcial effects on
he hematopoietic, immune and gastrointestinal systems,
ith positive repercussions on the quality of life of these
atients.15–24
Major metabolic alterations induced by advanced tumors
nclude glucose intolerance, decreased insulin secretion,
eripheral insulin resistance, increased synthesis and
lucose turnover, increased activity of the Cori cycle,
ncreased protein turnover, increased hepatic protein
ynthesis, increased muscle protein catabolism, reduced
lasma concentration of branched chain amino acids,
epletion of lipid deposits, increased lipolysis, increased
lycerol and free fatty acid turnover, reduced lipogenesis and
yperlipidemia.4,5,15,16,20,21,23
The depletion of adipose tissue is responsible, in large
art, by the weight loss observed in cancer patients. This is 5;3  5(1):28–34 33
due to the different changes in fatty acid metabolism and
also to the occurrence of lipolysis, increased lipid oxidation,
reduction of lipogenesis and of lipoprotein lipase activity, and
increased release of lipolytic tumor factors and hormone-
sensitive lipase, resulting in hyperlipidemia.15,16,19,20,22
The beneﬁcial effects of these fungi have been demon-
strated, with inhibition of anti-tumor activity and proliferation
of cancer cells, expansion of natural killer cell function and
of other immunological parameters, such as the secretion of
immunoglobulins IgA, IgM and IgE, and a progression of mono-
cyte and macrophage functions.5,16,21,22
It is noteworthy that, in addition to high biological value
proteins and of immunomodulator amino acids (such as argi-
nine and glutamine) that help in muscle protein anabolism
of cancer patients, other substances present in medicinal
fungi stand out: glucans, proteoglucans, lectins, ergosterol and
triterpenes – all with the ability of modulating the various
metabolic and immune actions in these patients.5,15,16,22,23
Conclusion
Our results suggest that dietary supplementation with Agar-
icus sylvaticus fungus has the ability to bring beneﬁt for
anthropometric parameters of women with colorectal cancer.
However, controlled and randomized clinical trials, in addi-
tion to those performed in this study, are needed to elucidate
the mechanisms of action of the bioactive principles present
in Agaricus sylvaticus,  as well as other medical conditions that
could beneﬁt through this supplementation.
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